Real-world evidence to advance knowledge in pulmonary hypertension: Status, challenges, and opportunities. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative's Real-world Evidence Working Group

Kellie Morland, Christian Gerges, Jean Elwing, Scott H. Visovatti, Jason Weatherald, Kari R. Gillmeyer, Sandeep Sahay, Stephen C. Mathai, Athénaïs Boucly, Paul G. Williams, Sivadasanpillai Harikrishnan, Evan P. Minty, Lukas Hobohm, Arun Jose, Roberto Badagliacca, Edmund M.T. Lau, Zhi Cheng Jing, Rebecca R. Vanderpool, Charles Fauvel, Jose Leonidas AlvesGeoff Strange, Tomas Pulido, Junyan Qian, Mengtao Li, Valentina Mercurio, Jason G.E. Zelt, Victor M. Moles, Meghan M. Cirulis, Sylvia M. Nikkho, Raymond L. Benza, C. Gregory Elliott

Research output: Contribution to journalArticlepeer-review

Abstract

This manuscript on real-world evidence (RWE) in pulmonary hypertension (PH) incorporates the broad experience of members of the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative Real-World Evidence Working Group. We aim to strengthen the research community's understanding of RWE in PH to facilitate clinical research advances and ultimately improve patient care. Herein, we review real-world data (RWD) sources, discuss challenges and opportunities when using RWD sources to study PH populations, and identify resources needed to support the generation of meaningful RWE for the global PH community.

Original languageEnglish (US)
Article numbere12317
Pages (from-to)e12317
JournalPulmonary Circulation
Volume13
Issue number4
DOIs
StatePublished - Oct 2023

Keywords

  • administrative claims data
  • electronic health records
  • patient-generated health data
  • real-world data
  • registries

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'Real-world evidence to advance knowledge in pulmonary hypertension: Status, challenges, and opportunities. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative's Real-world Evidence Working Group'. Together they form a unique fingerprint.

Cite this